30
Participants
Start Date
July 1, 2024
Primary Completion Date
July 1, 2028
Study Completion Date
July 1, 2029
Crizanlizumab
patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses).
control
Standard of care
Collaborators (1)
Novartis
INDUSTRY
Children's Hospital Los Angeles
OTHER